1. CONTROLLING SEVERE ALLERGIC ASTHMA WITH OMALIZUMAB (MONOCLONAL ANTI-IgE ANTIBODIES) IN CHILDREN.
- Author
-
Craiu, M., Stan, I. V., Comanici, V., Popescu, C., Valceanu, D., and Bumbacea, R.
- Subjects
- *
ASTHMA in children , *ALLERGIES , *MONOCLONAL antibodies , *PHENOTYPES , *ADRENOCORTICAL hormones - Abstract
Allergic severe asthma is rare disease among young children. Most of these patients should be evaluated by an expert and treatment has to be tailored according to evolutive phenotype. One option for adult patients with such a condition is adding omalizumab [anti-IgE antibodies] to step IV GINA medication. Authors present a small pediatric series of severe uncontrolled asthmatic patients treated with an average 12 months course of omalizumab. Demographics, clinical features and comorbid conditions are documented. Due to safety issues all patients were monitored during and after omalizumab injection in the resuscitation module of the Emergency Department from a tertiary referral pediatric hospital. Monitoring and protocol are presented. All children had a positive outcome, three with partial control and one with complete control. No serious side effects were observed. Low grade fever was easily controlled with trivial antipyretics. Conclusion: anti-IgE monoclonal antibodies in severe allergic asthma patients are efficacious also in children and represent a safe and solid alternative for long-term oral corticosteroid treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015